New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma.
about
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016Contrast Enhanced MRI in the Diagnosis of HCCMagnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acidCT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive ReviewNoninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining IssuesMultidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinomaHepatocellular carcinoma: a reviewHepatocellular carcinoma: A comprehensive reviewY90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular CarcinomaLI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications.An early look at the Organ Procurement and Transplantation Network explant pathology form data.Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.Natural history of liver imaging reporting and data system category 4 nodules in MRI.Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5.Current management of hepatocellular carcinoma.Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinomaRepeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines.Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cmValidating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.Quantitative assessment of washout in hepatocellular carcinoma using MRI.Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.Imaging of hepatocellular carcinoma and image guided therapies - how we do it.Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study.Hepatocellular carcinoma and cholangiocarcinoma: an update.Efficacy of the American Association for the Study of Liver Disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma.Hepatobiliary agents and their role in LI-RADS.Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ.LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma.Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?LI-RADS(®) ancillary features on CT and MRI.
P2860
Q26752478-78CB5455-948D-4B76-B056-93D66518EE0BQ26768472-8A899D65-3442-4131-AC1F-41B5038086FDQ26769602-B4A9955F-DE57-4359-AA54-3B5CF8ABF15FQ26770014-AEDB5E24-E1A3-48B6-BAB9-6AD0FC7A881BQ26770020-0D4A1732-E294-4E0B-BD36-2F966AF967A6Q26998606-631E60C0-1BE0-4145-A16F-DC2E7F77DE60Q26999411-81811162-EEE1-45B2-9509-6544F0D7ACB5Q28069290-839D9732-BA8F-4483-8E12-965B7718D44FQ28087638-1BB6ED21-8319-416D-A7B5-29672AC45EE7Q28314897-10C70190-5D7E-4442-A17A-25023158A64CQ30837374-20854AED-F234-4A98-B621-BCC968A67CBDQ30867625-22934675-D23C-434E-8F8F-98B9F22DBC0AQ31057437-FA87043D-5CBD-4490-BA3F-DD401B27D206Q31079301-7DCB4F43-0564-4A02-BCF1-669F5D06AAE2Q31090559-CEE89A0C-0BD4-40CE-BB31-F2FA228571E8Q31108230-DF85FC21-3435-4D8C-BC91-EE50EBC41562Q31118557-44C6CC1A-A348-4605-8171-7B16D2743E90Q31154548-1A899A06-8D2C-4796-8292-BADD06B7B0D7Q33582165-8A74C824-2A63-44A8-815D-902AC7ED0225Q34618735-5F14A62F-508B-406C-B226-175A7C6DD619Q34681046-AF618B3C-8357-48B1-BEF6-57CCC0ECFCA3Q34845074-4EBAF60A-7EF1-4CD3-9F70-5C007801D2AAQ34966816-0AC7B881-437B-4047-8870-A52DABE8C106Q34986180-479676D8-A252-4369-86C3-921B5DB02937Q34987874-C427A312-C20F-4DE9-80D2-0DB16B497EBBQ36147024-725927A5-0068-48C7-ADF4-13D9E19B5840Q36582635-9920AB30-1260-428E-987F-9DC78B24BA75Q37348887-60BE7442-97BB-400E-9166-FACB18612EC7Q37680183-542199DB-F875-4CE2-962B-811C71AC9445Q37685731-C6545EB3-A943-4F54-9247-B58D8B949DA1Q38163597-41EDC548-9914-40B7-A8A0-150EE3600348Q38202030-611EB3B2-5325-427B-8A78-6871ED68E4DCQ38257321-CB521FE0-4258-4C86-97A1-F82245AAEA74Q38399641-D68AE161-C49A-4BF2-A654-340ADF6246E7Q38560093-04F5878E-CD08-47C1-8993-851687CAD561Q38608806-AE9C0063-09BF-45CA-8EEF-D9B0A8C29814Q38614744-4A4C56FE-437F-4F74-8C3E-4D9681B5AFA4Q38630810-493B9605-4F91-435C-B913-B188A6E607DAQ38631276-590ABA47-CA16-44FF-AF2F-ADD4DB373DB5Q38710312-E41342BD-2739-43A1-A8A2-DD2844769BD6
P2860
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@en
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@nl
type
label
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@en
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@nl
prefLabel
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@en
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@nl
P2093
P356
P1433
P1476
New OPTN/UNOS policy for liver ...... g of hepatocellular carcinoma.
@en
P2093
Christoph Wald
Elizabeth A Pomfret
Hero K Hussain
Julie K Heimbach
Mark W Russo
P304
P356
10.1148/RADIOL.12121698
P407
P50
P577
2013-02-01T00:00:00Z